SCHEMBL1165249

SCHEMBL1165249

CCOB(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL96260 0.75
SCHEMBL50777 0.70 ALDH1A1 (0.32)
SCHEMBL27913833 0.70 ALDH1A1 (0.32)
SCHEMBL3890570 0.70 ALDH1A1 (0.32)
SCHEMBL7799284 0.69
SCHEMBL15641153 0.69
SCHEMBL7209996 0.67
Fluoride SCHEMBL23120036 0.67 ALDH1A1 (0.30)
SCHEMBL6154385 0.67 ALDH1A1 (0.30)
SCHEMBL3041911 0.67 ALDH1A1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025037567-A1 SUBSTRATE PROCESSING METHOD 東京エレクトロン株式会社 2025-02-20 WO claimed
US-8846915-B2 Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester AUROBINDO PHARMA LTD. (IN) 2014-09-30 US claimed
US-8759518-B2 Intermediates for the preparation of HMG CoA reductase inhibitors and processes for the preparation thereof CADILA HEALTHCARE LIMITED (IN) 2014-06-24 US claimed
US-20130158263-A1 INTERMEDIATES FOR THE PREPARATION OF HMG COA REDUCTASE INHIBITORS AND PROCESSES FOR THE PREPARATION THEREOF CADILA HEALTHCARE LIMITED (IN) 2013-06-20 US claimed
US-8212035-B2 Process for preparation of rosuvastatin calcium field of the invention AUROBINDO PHARMA LTD. (IN) 2012-07-03 US claimed
EP-2467363-A1 PROCESS FOR THE MANUFACTURE OF ROSUVASTATIN CALCIUM USING CRYSTALLINE ROSUVASTATIN ETHYL ESTER Aurobindo Pharma Limited (IN) 2012-06-27 EP claimed
US-20120149905-A1 PROCESS FOR THE MANUFACTURE OF ROSUVASTATIN CALCIUM USING CRYSTALLINE ROSUVASTATIN ETHYL ESTER AUROBINDO PHARMA LTD (IN) 2012-06-14 US claimed
WO-2011104725-A2 HMG-COA REDUCTASE INHIBITORS AND PROCESS FOR THE PREPARATION THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-09-01 WO claimed
WO-2011021058-A1 PROCESS FOR THE MANUFACTURE OF ROSUVASTATIN CALCIUM USING CRYSTALLINE ROSUVASTATIN ETHYL ESTER AUROBINDO PHARMA LIMITED (IN) 2011-02-24 WO claimed
US-20090312547-A1 PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM FIELD OF THE INVENTION AUROBINDO PHARMA LTD (IN) 2009-12-17 US claimed
EP-2125754-A1 AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM Aurobindo Pharma Limited (IN) 2009-12-02 EP claimed
WO-2009118598-A1 PROCESS FOR THE MANUFACTURE OF ROSUVASTATIN CALCIUM WITH HIGH PURITY AUROBINDO PHARMA LIMITED (IN) 2009-10-01 WO claimed
WO-2008096257-A1 AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM AUROBINDO PHARMA LIMITED (IN) 2008-08-14 WO claimed
WO-2025037567-A1 SUBSTRATE PROCESSING METHOD 東京エレクトロン株式会社 2025-02-20 WO disclosed
CN-112020520-B Method for producing allyl monomer copolymer having polar group 国立大学法人东京大学 2023-03-10 CN disclosed
US-20150228901-A1 POLYMER COMPOSITION AND POLYMER LIGHT-EMITTING DEVICE USING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-08-13 US disclosed
US-5369109-A Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids SAGAMI CHEMICAL RESEARCH CENTER (JP) 1994-11-29 US disclosed
EP-0475627-B1 Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids SAGAMI CHEM RES (JP) 1994-10-19 EP disclosed
US-5276154-A Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids SAGAMI CHEMICAL RESEARCH CENTER (JP) 1994-01-04 US disclosed
EP-0475627-A1 Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids SAGAMI CHEMICAL RESEARCH CENTER (JP) 1992-03-18 EP disclosed